Publications & Reports

Mitochondria, prostate cancer, and biopsy sampling error.

Parr RL, Mills J, Harbottle A, Creed JM, Crewdson G, Reguly B, Guimont FS
Department of Research, Mitomics Inc., Suite 1000, 290 Munro St., Thunder Bay, Ontario P7A 7T1, Canada.

Abstract

Mitochondria and their associated genome are emerging as sophisticated indicators of prostate cancer biology. Alterations in the mitochondrial genome (mtgenome) have been implicated in cell proliferation, metastatic behavior, androgen independence, as a signal for apoptosis, and as a predictor of biochemical recurrence. Somatic mutation patterns in complete mtgenomes are associated with prostate specific antigen levels (PSA) in prostate cancer patients and a large-scale mtgenome deletion (3.4 kb) is consistent with a prostate “cancerization” field effect. This review will focus on the biological characteristics of mitochondria and their direct clinical application to prostate cancer. Mitochondrial science is currently influencing clinical prostate cancer diagnostics and the rapid progress in this area indicates future, break-through contributions in the general field of oncology.

Publication

  • Journal: Discovery Medicine
  • Published: 01/04/2013
  • Volume: 15
  • Issue: 83
  • Pagination: 213-220